Harpoon therapeutics, inc. (HARP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities
Net loss

-12,552

-14,268

-15,908

-11,817

-13,579

-9,731

-6,760

-5,994

-4,881

Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense

847

643

592

467

369

211

174

140

147

Depreciation and amortization

503

500

-196

299

297

197

159

149

139

Non cash lease expense

98

92

348

474

288

-

-

-

-

Net amortization of discounts on marketable securities

-60

-

-

-

45

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

-

-

-

-

-

-

-

-

500

Prepaid expenses and other assets

3,055

781

-1,674

1,357

1,350

-345

90

641

121

Other assets

-12

11

54

-138

-2,969

-

-

-

-

Accounts payable

-1,090

-1,064

179

-105

-771

2,565

22

477

-509

Accrued liabilities

-573

-29

3,937

57

323

956

461

-10

-359

Deferred revenue

2,668

10,499

-1,417

-1,062

-1,063

-1,062

-1,063

-1,062

-1,063

Operating lease liabilities

-285

-156

-131

135

137

-

-

-

-

Deferred revenue, non current

-4,150

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

70

0

2

6

Net cash used in operating activities

-17,517

33,718

-11,237

-12,947

-12,425

-6,444

-7,102

-6,439

-7,141

Cash flows from investing activities
Purchases of property and equipment

5

369

1,754

1,321

72

157

191

223

92

Purchases of marketable securities

46,503

52,949

6,573

30,717

51,577

-

-

-

-

Maturities of marketable securities

11,192

-

-

-

-

-

-

-

-

Net cash used in investing activities

-35,316

-2,271

15,808

-31,203

-51,649

-157

-191

-223

-92

Cash flows from financing activities
Proceeds from initial public offering of common stock, net of commissions

-

-1

-17

191

70,473

-

-

-

-

Deferred offering costs

75

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options, net

340

526

116

127

34

24

102

22

10

Net cash provided by financing activities

265

525

99

318

70,507

68,236

20,058

22

10

Net increase (decrease) in cash, cash equivalents, and restricted cash

-52,568

31,972

4,670

-43,832

6,433

61,635

12,765

-6,640

-7,223

Supplemental disclosures of non-cash investing and financing information
Conversion of preferred stock to common stock and additional paid-in capital

-

0

0

0

129,577

-

-

-

-

Purchases of property and equipment included in accrued liabilities

90

-225

-1,954

2,172

23

-90

56

-148

210

Reclassification of employee stock liability to equity upon vesting

9

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued liabilities

167

-

-

-

-

-

-

-

-

Right-of-use asset obtained in exchange for lease obligation

-

1

0

0

8,404

-

-

-

-

Tenant improvements provided by landlord

-

61

-61

3,078

2,706

-

-

-

-

Initial public offering costs included in accounts payable

-

-

-

-

174

-

-

-

-